EPH receptor/ephrin system: in the quest for novel anti‐angiogenic therapies: Commentary on Hassan‐Mohamed  et al ., Br J Pharmacol 171: 5195–5208 | Zendy

Hatziapostolou M | Zendy; Polytarchou C | Zendy

Premium

EPH receptor/ephrin system: in the quest for novel anti‐angiogenic therapies: Commentary on Hassan‐Mohamed et al ., Br J Pharmacol 171: 5195–5208

Author(s) -

Hatziapostolou M,

Polytarchou C

Publication year - 2015

Publication title -

british journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.432

H-Index - 211

eISSN - 1476-5381

pISSN - 0007-1188

DOI - 10.1111/bph.12718

Subject(s) - erythropoietin producing hepatocellular (eph) receptor , ephrin , antagonist , in vitro , medicine , angiogenesis , receptor , pharmacology , chemistry , biochemistry , receptor tyrosine kinase

Linked Article This article is a Commentary on Hassan‐Mohamed I, Giorgio C, Incerti M, Russo S, Pala D, Pasquale EB, Zanotti I, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A and Tognolini M (2014). UniPR129 is a competitive small molecule Eph‐ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol 171: 5195–5208. doi: 10.1111/bph.12669

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research